"iDoctor – Medical Blog"

Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures [ndash] cost utility results for Sweden.Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2009.01320.x.© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard.Objectives [ndash] To calculate cost per additional quality-adjusted life-year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial-onset seizures as compared to no adjunctive treatment.Materials and methods [ndash] A decision-tree simulation model was constructed to calculate the number of seizures and health-care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs.Results [ndash] All results were calculated for a 24-, 18-, 12- and 6-months follow-up. The cost per additional QALY was estimated to [euro] 27,641 (24 months). Using a willingness-to-pay threshold for a QALY of [euro] 50,000 the net marginal value of using lacosamide was estimated to about [euro] 850,000 per 1000 patients.Conclusions [ndash] The estimated cost per QALY gained falls within the range of reported estimates of the willingness-to-pay for an additional QALY. The results imply that lacosamide is cost-effective in the treatment of uncontrolled partial-onset seizures (1 [euro] [asymp] 9.6 SEK).

This entry was posted on Tuesday, March 2nd, 2010 at 3:13 am and is filed under Health news. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.